Anaveon To Raise CHF 110 Million In Oversubscribed Series B Financing
21.12.2021
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led...
News
Cellestia Biotech receives Orphan Drug Designation from EU Commision
16.12.2021
Cellestia Biotech AG (Cellestia) is a fully integrated R&D company specialised in the discovery and development of first-in-class...
Kinarus receives 7 Million CHF Grant
14.12.2021
Kinarus AG has been awarded a grant from the Swiss Federal Funding Programme for the development of COVID-19 Medicines...
Versameb to present novel data on its lead asset
04.11.2021
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference...
Kinarus Secures CHF 57 Million Capital Commitment
14.09.2021
Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with...